+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Biologics CDMO Market - A Global and Regional Analysis, 2023-2033

  • PDF Icon

    Report

  • 165 Pages
  • November 2023
  • Region: Global
  • BIS Research
  • ID: 5909458
10% Free customization
Description Jump to:

Global Biologics CDMO Market Set to Surge, Riding the Wave of Innovation and Demand

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The global biologics CDMO market plays a crucial role in the pharmaceutical and biotechnology industries, offering specialized services for the development, manufacturing, and testing of biologic drugs. Biologics are complex molecules derived from living organisms, such as proteins, antibodies, and nucleic acids, and they have become increasingly important in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases.

CDMOs in the biologics sector provide a range of services, including cell line development, process development, scale-up, manufacturing, quality control, and regulatory support. These organizations serve as strategic partners for pharmaceutical and biotech companies, allowing them to outsource certain aspects of the drug development and manufacturing process, thereby gaining efficiency, expertise, and flexibility.

Market Segmentation:

Segmentation 1: by Cell Type

  • Mammalian
  • Non-mammalian

Segmentation 2: by Product Type

  • Biologics
  • Monoclonal Antibodies
  • Recombinant Proteins
  • Antisense and Molecular Therapy
  • Vaccines
  • Other Biologics
  • Biosimilars

Segmentation 3: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • MEA
The report provides data for each of these regions, with in-depth country-level analyses, all covering the period from 2022 to 2033.

How can this report add value to an organization?

Product/Innovation Strategy: The global biologics CDMO market has been extensively segmented based on various categories, such as cell type and product type. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.

Growth/Marketing Strategy: The global biologics CDMO market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint venture.

Competitive Strategy: Key players in the global biologics CDMO market analyzed and profiled in the study involve established and emerging players. Moreover, a detailed competitive benchmarking of the players operating in the global biologics CDMO market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analysing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

  • Boehringer Ingelheim Group
  • Lonza Group
  • Samsung Biologics
  • NOVARTIS AG
  • Toyobo Co. Limited
  • Parexel International Corporation
  • Catalent Inc.
  • Binex Co. Limited
  • AGC Biologics
  • AbbVie Contract Manufacturing


This product will be delivered within 3-5 business days.

Table of Contents

1 Markets: Industry Outlook
1.1 Trends: Current and Future Impact Assessment
1.1.1 Emerging Gene and Cell Therapies
1.1.2 Single-use Bioprocessing Equipment
1.1.3 Trend Toward Personalized Medicine
1.2 Supply Chain Overview
1.2.1 Value chain Analysis
1.2.2 Market Map
1.2.3 Cost of Manufacturing in CDMO/gm Forecast
1.3 Patent Analysis
1.3.1 Awaited Technological Developments
1.3.2 Patent Filing Trend by Country, by Year
1.3.3 Patent Filing Trend by Country, by Country
1.4 Regulatory Landscape
1.5 Prodution Capacity
1.6 Factors Considered While Outsourcing To CDMO
1.7 Impact analysis for key global events- covid19, Russia/Ukraine or Middle East crisis
1.8 Market Dynamics Overview
1.8.1 Market Drivers
1.8.2 Market Restraints
1.8.3 Market Opportunities
2 Application
2.1 Application Segmentation
2.2 Application Summary
2.3 Global Biologiv CDMO Market (by Cell Type)
2.3.1 Mammalian
2.3.2 Non-mammalian
3 Product
3.1 Product Segmentation
3.2 Product Summary
3.3 Global Biologics CDMO Market (by Product Type)
3.3.1 Biologics
3.3.1.1 Monoclonal Antibodies
3.3.1.2 Recombinant Proteins
3.3.1.3 Antisense and Molecular Therapy
3.3.1.4 Vaccines
3.3.1.5 Other Biologics
3.3.2 Biosimilars
4 Region
4.1 Regional Summary
Table: Biologics CDMO Market, By Region, ($ Million), 2022-2033
4.2 Drivers and Restraints
4.3 North America
Key Market Participants in North America
Business Drivers
Business Challenges
4.3.1 Application
Table: North America Biologics CDMO Market, By Cell Type ($ Million), 2022-2033
4.3.2 Product
Table: North America Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.3.3 North America (by Country)
4.3.3.1 U.S.
Table: U.S. Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
Table: U.S. Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.3.3.2 Canada
Table: U.S. Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
Table: U.S. Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.4 Europe
Key Market Participants in Europe
Business Drivers
Business Challenges
4.4.1 Application
Table: Europe Biologics CDMO Market, By Cell Type ($ Million), 2022-2033
4.4.2 Product
Table: Europe Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.4.3 Europe (by Country)
4.4.3.1 U.K.
Table: U.K.Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
Table: U.K. Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.4.3.2 Germany
Table: Germany Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
Table: Germany Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.4.3.3 Italy
Table: Italy Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
Table: Italy Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.4.3.4 France
Table: France Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
Table: France Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.4.3.5 Spain
Table: Spain Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
Table: Spain Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.4.3.6 Rest of Europe
Table: Rest of Europe Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
Table: Rest of Europe Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.5 Asia Pacific
Key Market Participants in Asia Pacific
Business Drivers
Business Challenges
4.5.1 Application
Table: Europe Biologics CDMO Market, By Cell Type ($ Million), 2022-2033
4.5.2 Product
Table: Europe Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.5.3 Asia Pacific (by Country)
4.5.3.1 China
Table: China Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
Table: China Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.5.3.2 Japan
Table: Japan Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
Table: Japan Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.5.3.3 India
Table: India Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
Table: India Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.5.3.4 Australia
Table: Australia Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
Table: Australia Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.5.3.5 Rest of APAC
Table: Rest of APAC Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
Table: Rest of APAC Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.6 Latin America
Key Market Participants in Latin America
Business Drivers
Business Challenges
4.6.1 Application
Table: Latin America Biologics CDMO Market, By Cell Type ($ Million), 2022-2033
4.6.2 Product
Table: Latin America Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.6.3 Latin America (by Country)
4.6.3.1 Brazil
Table: Brazil Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
Table: Brazil Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.6.3.2 Mexico
Table: Mexico Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
Table: Mexico Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.6.3.3 Rest of Latin America
Table: Rest of Latin America Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
Table: Rest of Latin America Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.7 MEA
Key Market Participants in MEA
Business Drivers
Business Challenges
4.7.1 Application
Table: MEA Biologics CDMO Market, By Cell Type ($ Million), 2022-2033
4.7.2 Product
Table: MEA Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.7.3 MEA (by Country)
4.7.3.1 Saudi Arabia
Table: Saudi Arabia Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
Table: Saudi Arabia Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.7.3.2 U.A.E.
Table: U.A.E. Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
Table: U.A.E. Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
4.7.3.3 Rest of MEA
Table: Rest of MEA Biologics CDMO Market Market, By Cell Type ($ Million), 2022-2033
Table: Rest of MEA Biologics CDMO Market Market, By Product Type ($ Million), 2022-2033
5 Markets - Competitive Landscape & Company Profiles
5.1 Competitive Landscape
5.2 Company Profile
5.2.1 Boehringer Ingelheim Group
5.2.1.1 Company Overview
5.2.1.1.1 Role of Boehringer Ingelheim Group in Biologics CDMO Market
5.2.1.1.2 Product Portfolio
5.2.1.2 Business Strategies
5.2.1.3 Corporate Strategies
5.2.1.4 Analyst View
5.2.2 Lonza Group
5.2.2.1 Company Overview
5.2.2.1.1 Role of Lonza Group in Biologics CDMO Market
5.2.2.1.2 Product Portfolio
5.2.2.2 Business Strategies
5.2.2.3 Corporate Strategies
5.2.2.4 Analyst View
5.2.3 Samsung Biologics
5.2.3.1 Company Overview
5.2.3.1.1 Role of Samsung Biologics in Biologics CDMO Market
5.2.3.1.2 Product Portfolio
5.2.3.2 Business Strategies
5.2.3.3 Corporate Strategies
5.2.3.4 Analyst View
5.2.4 NOVARTIS AG
5.2.4.1 Company Overview
5.2.4.1.1 Role of NOVARTIS AG in Biologics CDMO Market
5.2.4.1.2 Product Portfolio
5.2.4.2 Business Strategies
5.2.4.3 Corporate Strategies
5.2.4.4 Analyst View
5.2.5 Toyobo Co. Limited
5.2.5.1 Company Overview
5.2.5.1.1 Role of Toyobo Co. Limited Group in Biologics CDMO Market
5.2.5.1.2 Product Portfolio
5.2.5.2 Business Strategies
5.2.5.3 Corporate Strategies
5.2.5.4 Analyst View
5.2.6 Parexel International Corporation
5.2.6.1 Company Overview
5.2.6.1.1 Role of Parexel International Corporation in Biologics CDMO Market
5.2.6.1.2 Product Portfolio
5.2.6.2 Business Strategies
5.2.6.3 Corporate Strategies
5.2.6.4 Analyst View
5.2.7 Catalent Inc.
5.2.7.1 Company Overview
5.2.7.1.1 Role of Catalent Inc. in Biologics CDMO Market
5.2.7.1.2 Product Portfolio
5.2.7.2 Business Strategies
5.2.7.3 Corporate Strategies
5.2.7.4 Analyst View
5.2.8 Binex Co. Limited
5.2.8.1 Company Overview
5.2.8.1.1 Role of Binex Co. Limited in Biologics CDMO Market
5.2.8.1.2 Product Portfolio
5.2.8.2 Business Strategies
5.2.8.3 Corporate Strategies
5.2.8.4 Analyst View
5.2.9 AGC Biologics
5.2.9.1 Company Overview
5.2.5.1.1 Role of AGC Biologics in Biologics CDMO Market
5.2.5.1.2 Product Portfolio
5.2.9.2 Business Strategies
5.2.9.3 Corporate Strategies
5.2.9.4 Analyst View
5.2.10 AbbVie Contract Manufacturing
5.2.10.1 Company Overview
5.2.10.1.1 Role of AbbVie Contract Manufacturing in Biologics CDMO Market
5.2.10.1.2 Product Portfolio
5.2.10.2 Business Strategies
5.2.10.3 Corporate Strategies
5.2.10.4 Analyst View

Executive Summary

The biologics CDMO market has experienced a significant surge in demand, driven by the increasing adoption of biopharmaceuticals, advancements in bioprocessing technologies, and the expanding pipeline of biologics in various therapeutic areas. The market has become a focal point for pharmaceutical and biotechnology companies seeking strategic partnerships to accelerate the development and commercialization of their biologic products.

Key Highlights from the Report:

Market Overview: An overview of the global biologics CDMO market, including its size, growth potential, and key drivers.

Market Dynamics: In-depth analysis of market trends, drivers, challenges, and opportunities influencing the biologics CDMO industry.

Competitive Landscape: Analysis of the competitive landscape, including profiles of major market players, their strategies, and market shares.

Regional Analysis: Examination of the market's performance in different regions, including North America, Europe, Asia-Pacific, Latin America, and MEA.

Growth Prospects: Assessment of growth opportunities and challenges in the global biologics CDMO market, along with future market projections.

Analyst Perspective

According to the Principal Analyst, 'The global biologics CDMO market is experiencing a paradigm shift, with an increasing number of pharmaceutical companies recognizing the strategic advantages of outsourcing. This trend is driven by the need for accelerated development timelines, cost efficiency, and access to cutting-edge technologies. CDMOs are becoming pivotal partners in the biopharmaceutical ecosystem, playing a crucial role in bringing innovative therapies to market.'

Some of the prominent names established in this market are:

  • Boehringer Ingelheim Group
  • Lonza Group
  • Samsung Biologics
  • NOVARTIS AG
  • Toyobo Co. Limited
  • Parexel International Corporation
  • Catalent Inc.
  • Binex Co. Limited
  • AGC Biologics
  • AbbVie Contract Manufacturing

Key Questions Answered in the Report:

  • What is the estimated global biologics CDMO market size in terms of revenue for the forecast period 2023-2033, and what is the expected compound annual growth rate (CAGR) during the forecast period 2023-2033?
  • What are the key market drivers and opportunities in the market pertaining to biologics CDMO?
  • What are the major restraints inhibiting the growth of the global biologics CDMO market?
  • What kinds of new strategies are being adopted by the existing market players to expand their market position in the industry?

Companies Mentioned

  • Boehringer Ingelheim Group
  • Lonza Group
  • Samsung Biologics
  • NOVARTIS AG
  • Toyobo Co. Limited
  • Parexel International Corporation
  • Catalent Inc.
  • Binex Co. Limited
  • AGC Biologics
  • AbbVie Contract Manufacturing

Related Topics

Related Reports

Biologics CDMO Global Market Report 2024 - Product Image

Biologics CDMO Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Biologics CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029 - Product Image

Biologics CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

  • Report
  • 179 Pages
  • Global
From
Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Global Market Report 2024 - Product Image

Cell and Gene Therapy Contract Development and Manufacturing Organization (CDMO) Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
CDMO Market Opportunities and Competitive Landscape - Product Image

CDMO Market Opportunities and Competitive Landscape

  • Report
  • 130 Pages
  • Global
From
Cell and Gene Therapy CDMO Market: Analysis By Type, Application, Indication, By Region, By Country: Market Insights and Forecast - Product Image

Cell and Gene Therapy CDMO Market: Analysis By Type, Application, Indication, By Region, By Country: Market Insights and Forecast

  • Report
  • 260 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.